GlassScriptPhysician profile
Rosaura Rios
NPI 1649907569
$4,074.76
in general payments reported to CMS, 2019-2025
22 companies · $1,961 in 2025
The $1,961 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $167 · 2023: $862 · 2024: $1,084 · 2025: $1,961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,908.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $566.98 | 2024-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $548.67 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $488.89 | 2022-2025 | Mounjaro, Jardiance, Trulicity |
| Astrazeneca Pharmaceuticals LP | $358.09 | 2023 | Farxiga, Breztri |
| Amgen INC. | $314.83 | 2023-2025 | Tepezza, Repatha, Repatha |
| Corcept Therapeutics | $222.64 | 2024-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.97 | 2024-2025 | Jardiance |
| Insulet Corporation | $218.18 | 2024-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $177.03 | 2025 | Gvoke Hypopen |
| Madrigal Pharmaceuticals | $150.00 | 2024 | Rezdiffra |
| Medtronic, INC. | $145.48 | 2024 | Minimed 780g |
| Ascendis Pharma Endocrinology INC | $143.81 | 2025 | Yorvipath |
| Bayer Healthcare Pharmaceuticals INC. | $100.30 | 2024-2025 | |
| Mannkind Corporation | $98.25 | 2025 | |
| Glaxosmithkline, LLC. | $89.93 | 2023-2024 | Trelegy Ellipta, Shingrix |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $50.17 | 2023-2024 | Cologuard Collection Kit |
| Optinose US, INC. | $45.62 | 2022-2023 | |
| Esperion Therapeutics, INC. | $41.66 | 2024-2025 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.69 | 2023 | Xifaxan |
| Sequel Med Tech, LLC | $25.00 | 2025 | Twiist |
| Novartis Pharmaceuticals Corporation | $21.82 | 2024 | |
| Neurocrine Biosciences, INC. | $20.75 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosaura Rios listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.